• Tenax Therapeutics director Declan Doogan bought 53,000 common shares at USD 1.92, lifting direct holdings to 55,274 shares.
• Doogan also reported stock options covering 210,008 shares, with exercise prices ranging from USD 5.75 to USD 3,200.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenax Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-394831), on September 17, 2026, and is solely responsible for the information contained therein.